Microarray and ChIP‑seq data analysis revealed changes in p53-mediated transcriptional regulation in Nutlin-3-treated U2OS cells

Zhao,Song; Niu,Feng; Xu,Chang‑Yan; Ye,Long; Bi,Gui‑Bin; Chen,Lin; Gong,Ping; Tian,Gang; Nie,Tian‑Hong

doi:10.3892/mmr.2015.3933

Microarray and ChIP‑seq data analysis revealed changes in p53-mediated transcriptional regulation in Nutlin-3-treated U2OS cells

Authors:
- Song Zhao
- Feng Niu
- Chang‑Yan Xu
- Long Ye
- Gui‑Bin Bi
- Lin Chen
- Ping Gong
- Gang Tian
- Tian‑Hong Nie
View Affiliations

Affiliations: Department of Spinal Surgery, The First Hospital of Jilin University, Changchun, Jilin 130021, P.R. China, Department of Medical Records, The First Hospital of Jilin University, Changchun, Jilin 130021, P.R. China
Published online on: June 15, 2015 https://doi.org/10.3892/mmr.2015.3933
Pages: 4284-4290
Copyright: © Zhao et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Integrative analysis of chromatin immunoprecipitation-sequencing (ChIP-seq) data and microarray data was performed to illustrate the effect of Nutlin‑3 on promoter selectivity and transcriptional regulation by the tumor suppressor p53 in U2OS human osteosarcoma cells. Raw data (accession number, GSE46642) were downloaded from Gene Expression Omnibus. Differential analyses were performed using package limma of R software. Gene ontology enrichment and Kyoto Encyclopedia of Genes and Genomes pathway enrichment analyses were performed for the differentially expressed genes (DEGs) using the Database for Annotation, Visualization and Integration Discovery. Integrative analysis of ChIP‑seq data and microarray data were confirmed with ChIP‑Array. A total of 565 DEGs were identified, including 373 upregulated genes and 192 downregulated genes. Genes involved in the p53 signaling pathway, cell cycle, DNA replication, cytokine‑cytokine receptor interaction and melanoma were markedly over‑represented in the DEGs. A total of 39 DEGs were directly regulated by p53 and two were the transcription factors (TFs), E2F2 and HOXA1. E2F2 regulated 25 DEGs, while HOXA1 regulated one DEG. The cell cycle, p53 signaling pathway, melanoma and pathways involved in cancer were enriched in the direct and indirect target genes. Changes in the p53‑binding pattern induced by Nutlin‑3 were described in the present study, which may advance the understanding of the regulatory network of p53 in osteosarcoma and aid in the development of novel therapies.

View Figures

View References

1	Espinosa JM: Mechanisms of regulatory diversity within the p53 transcriptional network. Oncogene. 27:4013–4023. 2008. View Article : Google Scholar : PubMed/NCBI
2	Menendez D, Inga A and Resnick MA: The expanding universe of p53 targets. Nat Rev Cancer. 9:724–737. 2009. View Article : Google Scholar : PubMed/NCBI
3	Riley T, Sontag E, Chen P and Levine A: Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol. 9:402–412. 2008. View Article : Google Scholar : PubMed/NCBI
4	Miller LD, Smeds J, George J, Vega VB, Vergara L, Ploner A, Pawitan Y, Hall P, Klaar S, Liu ET and Bergh J: An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects and patient survival. Proc Natl Acad Sci USA. 102:13550–13555. 2005. View Article : Google Scholar
5	Wei CL, Wu Q, Vega VB, Chiu KP, Ng P, Zhang T, Shahab A, Yong HC, Fu Y, Weng Z, et al: A global map of p53 transcription-factor binding sites in the human genome. Cell. 124:207–219. 2006. View Article : Google Scholar : PubMed/NCBI
6	Bruna A, Darken RS, Rojo F, Ocaña A, Peñuelas S, Arias A, Paris R, Tortosa A, Mora J, Baselga J and Seoane J: High TGFβ-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene. Cancer Cell. 11:147–160. 2007. View Article : Google Scholar : PubMed/NCBI
7	Rozan L and El-Deiry W: p53 downstream target genes and tumor suppression: A classical view in evolution. Cell Death Differ. 14:3–9. 2006. View Article : Google Scholar : PubMed/NCBI
8	Botcheva K, McCorkle SR, McCombie W, Dunn JJ and Anderson CW: Distinct p53 genomic binding patterns in normal and cancer-derived human cells. Cell Cycle. 10:4237–4249. 2011. View Article : Google Scholar : PubMed/NCBI
9	Smeenk L, Van Heeringen SJ, Köppel M, Gilbert B, Janssen-Megens E, Stunnenberg HG and Lohrum M: Role of p53 serine 46 in p53 target gene regulation. PloS One. 6:e175742011. View Article : Google Scholar : PubMed/NCBI
10	Smeenk L, van Heeringen SJ, Koeppel M, van Driel MA, Bartels SJ, Akkers RC, Denissov S, Stunnenberg HG and Lohrum M: Characterization of genome-wide p53-binding sites upon stress response. Nucleic Acids Res. 36:3639–3654. 2008. View Article : Google Scholar : PubMed/NCBI
11	Jaffe N, Bruland OS and Bielack S: Pediatric and adolescent osteosarcoma. Springer; New York, NY: pp. 275–287. 2010
12	Ottaviani G and Jaffe N: The epidemiology of osteosarcoma. Cancer Treat Res. 3–13. 2010.PubMed/NCBI
13	Menendez D, Nguyen TA, Freudenberg JM, Mathew VJ, Anderson CW, Jothi R and Resnick MA: Diverse stresses dramatically alter genome-wide p53 binding and transactivation landscape in human cancer cells. Nucleic Acids Res. 41:7286–7301. 2013. View Article : Google Scholar : PubMed/NCBI
14	Gautier L, Cope L, Bolstad BM and Irizarry RA: Affy-analysis of Affymetrix GeneChip data at the probe level. Bioinformatics. 20:307–315. 2004. View Article : Google Scholar : PubMed/NCBI
15	Diboun I, Wernisch L, Orengo CA and Koltzenburg M: Microarray analysis after RNA amplification can detect pronounced differences in gene expression using limma. BMC Genomics. 7:2522006. View Article : Google Scholar : PubMed/NCBI
16	Qin J, Li MJ, Wang P, Zhang MQ and Wang J: ChIP-Array: combinatory analysis of ChIP-seq/chip and microarray gene expression data to discover direct/indirect targets of a transcription factor. Nucleic Acids Res. 39:W430–W436. 2011. View Article : Google Scholar : PubMed/NCBI
17	Huang DW, Sherman BT, Tan Q, Collins JR, Alvord WG, Roayaei J, Stephens R, Baseler MW, Lane HC and Lempicki RA: The DAVID Gene Functional Classification Tool: A novel biological module-centric algorithm to functionally analyze large gene lists. Genome Biol. 8:R1832007. View Article : Google Scholar : PubMed/NCBI
18	Diller L, Kassel J, Nelson CE, Gryka MA, Litwak G, Gebhardt M, Bressac B, Ozturk M, Baker SJ and Vogelstein B: p53 functions as a cell cycle control protein in osteosarcomas. Mol Cell Biol. 10:5772–5781. 1990.PubMed/NCBI
19	Overholtzer M, Rao PH, Favis R, Lu XY, Elowitz MB, Barany F, Ladanyi M, Gorlick R and Levine AJ: The presence of p53 mutations in human osteosarcomas correlates with high levels of genomic instability. Proc Natl Acad Sci USA. 100:11547–11552. 2003. View Article : Google Scholar : PubMed/NCBI
20	Berman SD, Calo E, Landman AS, Danielian PS, Miller ES, West JC, Fonhoue BD, Caron A, Bronson R, Bouxsein ML, et al: Metastatic osteosarcoma induced by inactivation of Rb and p53 in the osteoblast lineage. Proc Natl Acad Sci USA. 105:11851–11856. 2008. View Article : Google Scholar : PubMed/NCBI
21	Nakase M, Inui M, Okumura K, Kamei T, Nakamura S and Tagawa T: p53 gene therapy of human osteosarcoma using a transferrin-modified cationic liposome. Mol Cancer Ther. 4:625–631. 2005. View Article : Google Scholar : PubMed/NCBI
22	Momand J, Wu H-H and Dasgupta G: MDM2-master regulator of the p53 tumor suppressor protein. Gene. 242:15–29. 2000. View Article : Google Scholar : PubMed/NCBI
23	Chène P: Inhibiting the p53-MDM2 interaction: An important target for cancer therapy. Nat Rev Cancer. 3:102–109. 2003. View Article : Google Scholar : PubMed/NCBI
24	Klein C and Vassilev LT: Targeting the p53-MDM2 interaction to treat cancer. Br J Cancer. 91:1415–1419. 2004.PubMed/NCBI
25	Zhang Y, Shu L and Chen X: Syntaxin 6, a regulator of the protein trafficking machinery and a target of the p53 family, is required for cell adhesion and survival. J Biol Chem. 283:30689–30698. 2008. View Article : Google Scholar : PubMed/NCBI
26	Bouleau S, Grimal H, Rincheval V, Godefroy N, Mignotte B, Vayssière JL and Renaud F: FGF1 inhibits p53-dependent apoptosis and cell cycle arrest via an intracrine pathway. Oncogene. 24:7839–7849. 2005. View Article : Google Scholar : PubMed/NCBI
27	Sutton AL, Zhang X, Ellison TI and MacDonald PN: The 1, 25 (OH) 2D3-regulated transcription factor MN1 stimulates vitamin D receptor-mediated transcription and inhibits osteoblastic cell proliferation. Mol Endocrinol. 19:2234–2244. 2005. View Article : Google Scholar : PubMed/NCBI
28	Zhang X, Dowd DR, Moore MC, Kranenburg TA, Meester-Smoor MA, Zwarthoff EC and MacDonald PN: Meningioma 1 is required for appropriate osteoblast proliferation, motility, differentiation and function. J Biol Chem. 284:18174–18183. 2009. View Article : Google Scholar : PubMed/NCBI
29	Zhu JW, Field SJ, Gore L, Thompson M, Yang H, Fujiwara Y, Cardiff RD, Greenberg M, Orkin SH and DeGregori J: E2F1 and E2F2 determine thresholds for antigen-induced T-cell proliferation and suppress tumorigenesis. Mol Cell Biol. 21:8547–8564. 2001. View Article : Google Scholar : PubMed/NCBI
30	Pusapati RV, Weaks RL, Rounbehler RJ, McArthur MJ and Johnson DG: E2F2 suppresses Myc-induced proliferation and tumorigenesis. Mol Carcinog. 49:152–156. 2010.
31	Laresgoiti U, Apraiz A, Olea M, Mitxelena J, Osinalde N, Rodriguez JA, Fullaondo A and Zubiaga AM: E2F2 and CREB cooperatively regulate transcriptional activity of cell cycle genes. Nucleic Acids Res. 41:10185–10198. 2013. View Article : Google Scholar : PubMed/NCBI
32	Mohankumar KM, Xu X, Zhu T, Kannan N, Miller LD, Liu ET, Gluckman PD, Sukumar S, Emerald BS and Lobie PE: HOXA1-stimulated oncogenicity is mediated by selective upregulation of components of the p44/42 MAP kinase pathway in human mammary carcinoma cells. Oncogene. 26:3998–4008. 2007. View Article : Google Scholar : PubMed/NCBI
33	Bitu CC, Destro MF, Carrera M, da Silva SD, Graner E, Kowalski LP, Soares FA and Coletta RD: HOXA1 is overexpressed in oral squamous cell carcinomas and its expression is correlated with poor prognosis. BMC cancer. 12:1462012. View Article : Google Scholar : PubMed/NCBI
34	Enomoto M, Hayakawa S, Itsukushima S, Ren DY, Matsuo M, Tamada K, Oneyama C, Okada M, Takumi T, Nishita M, et al: Autonomous regulation of osteosarcoma cell invasiveness by Wnt5a/Ror2 signaling. Oncogene. 28:3197–3208. 2009. View Article : Google Scholar : PubMed/NCBI